Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jacob P. Lalezari M.D. | CEO & Member of Scientific Advisory Board | 356.06k | -- | 1960 |
| Mr. Mitchell M. Cohen | Interim Chief Financial Officer | 655.2k | -- | 1956 |
| Mr. Tyler Blok | Chief Legal Officer & Corporate Secretary | 399.77k | -- | 1987 |
| Dr. Cyrus Arman M.B.A., Ph.D. | Senior Vice President of Business Operations | 278.1k | -- | 1981 |
| Dr. Bernie Cunningham P.M.P., Ph.D. | Vice President of Operations | -- | -- | -- |
| Dr. Scott Hansen Ph.D. | Head of Research & Basic Science | -- | -- | -- |
| Dr. Max Lataillade D.O., M.P.H. | Senior VP & Head of Clinical Development | -- | -- | -- |
| Ms. Cristina De Leon | Investors | -- | -- | -- |
CytoDyn Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 9
Description
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Corporate Governance
Upcoming Events
April 14, 2025 at 8:00 PM UTC - April 18, 2025 at 8:00 PM UTC
CytoDyn Inc. Earnings Date
Recent Events
September 26, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission